Announced details
The parties are related through the presentation of academic findings on a pharmaceutical product under development by the Company. Capital, personnel, and business relationships: not disclosed
The association holding the EHA 2026 Congress. Location, representative, business activities, capital, and year established: not disclosed
NCT05602363 (clinical trial identification number)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Abstract URL for EHA 2026 (https://library.ehaweb.org/eha/2026/eha-2026/4208242/)
| Item | Details |
|---|---|
| Names of Products / Services Covered | docirbrutinib (AS-1763) |
| Counterparty | European Hematology Association (EHA) |
| Counterparty overview | The association holding the EHA 2026 Congress. Location, representative, business activities, capital, and year established: not disclosed |
| Relationship with the Company | The parties are related through the presentation of academic findings on a pharmaceutical product under development by the Company. Capital, personnel, and business relationships: not disclosed |
| Launch date | 13 June 2026 (scheduled; presentation date) |
| Applicable area | Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), B-cell non-Hodgkin lymphoma (B-cell NHL), Mature B-cell malignancies |
| Registration number and expiry date | NCT05602363 (clinical trial identification number) |
| Source | Abstract URL for EHA 2026 (https://library.ehaweb.org/eha/2026/eha-2026/4208242/) |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The latest clinical trial data on docirbrutinib's Phase 1b trial will be presented at EHA 2026.